Clinical and pathological or molecular data from reports identified in our literature review suggest that the development of sarcoma is more often associated with MSH2 pathogenic variants than with other LS genes, as 25 out of 43 (58.1%) cases subjected to genetic testing harbored mutations in this gene. The gene discussed is LIAS; the disease is sarcoma.